Jaguar Health, Inc. (JAGX) stock
JAGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.35−0.03 (-7.03%)
Close on Nov 18, 2026Market cap $1.83MP/E –Yield –
Jaguar Health operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Jaguar Health's operating income for the twelve months ending Jun 30, 2026 was -$25.90M. For fiscal 2025 it was -$45.91M. The highest annual figure on record is -$8.32M in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$45.91M | – |
| FY2024 | Dec 31, 2024 | -$30.83M | – |
| FY2023 | Dec 31, 2023 | -$34.29M | – |
| FY2022 | Dec 31, 2022 | -$34.42M | – |
| FY2021 | Dec 31, 2021 | -$40.71M | – |
| FY2020 | Dec 31, 2020 | -$26.65M | – |
| FY2019 | Dec 31, 2019 | -$28.95M | – |
| FY2018 | Dec 31, 2018 | -$30.82M | – |
| FY2017 | Dec 31, 2017 | -$34.25M | – |
| FY2016 | Dec 31, 2016 | -$13.59M | – |
| FY2015 | Dec 31, 2015 | -$12.45M | – |
| FY2014 | Dec 31, 2014 | -$8.32M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.60M | – |
| Q1 FY2026 | Mar 31, 2026 | $10.18M | – |
| Q4 FY2025 | Dec 31, 2025 | -$21.24M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.24M | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.01M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.42M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.16M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.26M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.20M | – |
| Q1 FY2024 | Mar 31, 2024 | -$8.22M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.56M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.79M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.10M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.85M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.29M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.90M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.48M | – |
| Q1 FY2022 | Mar 31, 2022 | -$11.75M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.82M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.53M | – |
| Q2 FY2021 | Jun 30, 2021 | -$11.58M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.77M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.17M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.38M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.45M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.65M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.82M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.73M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.62M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.78M | – |
| Q4 FY2018 | Dec 31, 2018 | -$12.11M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.51M | – |
| Q4 FY2017 | Dec 31, 2017 | -$20.68M | – |
| Q3 FY2017 | Sep 30, 2017 | -$7.34M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.35M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.88M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.31M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.18M | – |
| Q2 FY2016 | Jun 30, 2016 | -$3.41M | – |
See a number that looks wrong?